By Melanie Senior
At last, German conglomerate Bayer AG is taking visible steps to save its struggling health care division. Since the...
Bayer: Out of Trouble Come Opportunities
Bayer's respiratory diseases spin-out Aerovance shows how new opportunities are springing out of Europe's mid-sized firms, many of which are in transition.
More from Archive
More from In Vivo
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.